News stories about Omnicell (NASDAQ:OMCL) have trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Omnicell earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.2548816462358 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
A number of equities analysts recently commented on the company. Zacks Investment Research lowered Omnicell from a “hold” rating to a “sell” rating in a research note on Wednesday. Oppenheimer reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Omnicell in a research note on Tuesday, December 5th. Craig Hallum reaffirmed a “buy” rating and issued a $62.00 price objective (up from $52.00) on shares of Omnicell in a research note on Monday, October 30th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Omnicell in a research note on Tuesday, December 5th. Finally, BidaskClub lowered Omnicell from a “hold” rating to a “sell” rating in a research note on Friday, December 22nd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. Omnicell currently has an average rating of “Hold” and an average price target of $55.14.
Omnicell (NASDAQ:OMCL) opened at $50.75 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.53 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $1,913.69, a P/E ratio of -461.36, a P/E/G ratio of 4.00 and a beta of 0.71. Omnicell has a 12 month low of $32.35 and a 12 month high of $55.40.
In other Omnicell news, VP Peter J. Kuipers sold 4,724 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $47.74, for a total value of $225,523.76. Following the transaction, the vice president now directly owns 40,544 shares of the company’s stock, valued at $1,935,570.56. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Jorge R. Taborga sold 6,295 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $48.69, for a total value of $306,503.55. Following the completion of the transaction, the vice president now directly owns 50,013 shares in the company, valued at $2,435,132.97. The disclosure for this sale can be found here. Over the last three months, insiders sold 27,558 shares of company stock worth $1,330,230. Insiders own 3.77% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Omnicell (OMCL) Receives Daily Media Impact Score of 0.14” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.com-unik.info/2018/01/14/omnicell-omcl-receives-daily-media-impact-score-of-0-14.html.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.